Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Acrizanib (LHA510) 是一种 VEGFR-2 的抑制剂,其对 BaF3-VEGFR-2 的 IC50 值为 17.4 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,160 | 现货 | ||
2 mg | ¥ 1,680 | 现货 | ||
5 mg | ¥ 2,660 | 现货 | ||
10 mg | ¥ 4,230 | 现货 | ||
25 mg | ¥ 6,630 | 现货 | ||
50 mg | ¥ 8,930 | 现货 | ||
100 mg | ¥ 11,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,920 | 现货 |
产品描述 | Acrizanib (LHA510) is a VEGFR-2 inhibitor, with an IC50 of 17.4 nM for BaF3-VEGFR-2. |
体外活性 | Acrizanib is a VEGFR-2 inhibitor, with an IC50 of 17.4 nM for BaF3-KDR. Acrizanib exhibits ≤10% remaining kinase activity against only 13 wild type kinases: CSF1R, Kit, PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, Fms (soluble VEGFR1), DDR1, DDR2, TIE1, and ABL1 (nonphosphorylated)[1]. |
体内活性 | Rat ocular PK studies with Acrizanib (compound 35) shows a distinctly different profile from that observed with compound 25. While prolonged exposure is once again evident in the PEC, the AUC ratio to the level of Acrizanib in plasma is markedly increased (>21000-fold higher exposure in the PEC than plasma on day 11). Furthermore, unlike 25, Acrizanib also afford much improved retina to plasma AUC exposure ratio after 10 days of dosing (598× for Acrizanib vs 0.8× for 25)[1]. |
别名 | LHA510 |
分子量 | 445.4 |
分子式 | C20H18F3N7O2 |
CAS No. | 1229453-99-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 37.8 mg/mL (84.9 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2452 mL | 11.2259 mL | 22.4517 mL | 56.1293 mL |
5 mM | 0.449 mL | 2.2452 mL | 4.4903 mL | 11.2259 mL | |
10 mM | 0.2245 mL | 1.1226 mL | 2.2452 mL | 5.6129 mL | |
20 mM | 0.1123 mL | 0.5613 mL | 1.1226 mL | 2.8065 mL | |
50 mM | 0.0449 mL | 0.2245 mL | 0.449 mL | 1.1226 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Acrizanib 1229453-99-9 Angiogenesis Tyrosine Kinase/Adaptors VEGFR LHA-510 LHA510 LHA 510 Inhibitor inhibitor inhibit